Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 143

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 143
---
 to the Company and the Purchaser, and satisfaction or waiver of all other conditions set forth
in the Agreement, the Company expects the Effective Date to occur on or before January 30, 2026. It is not possible, however, to state with certainty when the Effective Date will occur. The Effective Date could be delayed for a number of
reasons, including the failure to satisfy the conditions to the completion of the Arrangement in the anticipated time frames.

Canadian Securities Law Matters

The Company is a reporting issuer in Québec, and, accordingly, is subject to MI
61-101. For a discussion of MI 61-101, please see “Interests of the Company’s Directors and Executive Officers in the Arrangement — CanadianSecurities Law Matters.”

Other Regulatory Matters

Following the completion of the Arrangement, the Common Shares will be delisted from Nasdaq and deregistered under the U.S. Exchange Act, in
each case, in accordance with applicable Laws, rules and regulations, and the Company’s reporting obligations under the U.S. Exchange Act with respect to the Common Shares will be terminated. Similarly, the Company will make an application to
cease to be a reporting issuer in Québec following the implementation of which, the Company will cease to have public reporting obligations under Securities Laws.

86

THE CVR AGREEMENT

At or prior to the time at which the Arrangement becomes effective, Parent and Purchaser will authorize and duly adopt, execute and deliver,
and will ensure that a rights agent mutually agreeable to Parent and the Company executes and delivers, a CVR Agreement. Each CVR will represent a contractual right to receive contingent cash payments equal to: (i) 100% of certain additional
receivables that may be received by the Company within ninety (90) days following Closing (net of certain permitted deductions incurred in connection therewith); (ii) a percentage of the net proceeds received from the Company’s existing
partnerships with Bristol-Myers Squibb, Debiopharm, and DCx, as follows: (a) 90% received from the Closing date until the 2nd anniversary thereof, (b) 85% received from the 2nd anniversary of the Closing date until the 4th anniversary of the Closing
date until the 6th anniversary of the Closing date, (c) 80% received from the 4th anniversary of the Closing date until the 6th anniversary of the Closing date, and (d) 75